3 recruiting. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 3 |
Follow ALL: new trials by email Literature Review of ALL trials Research Report on ALL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multicenter Study of CAR-T Cells in Primary Ph+All CD19 CAR-T cells - ALL | Phase 2 | Recruiting | Zhejiang University | 50 | 2025-11-30 | 2025-12-04 |
| Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL Inotuzumab Ozogamicin - ALL, MRD-positive | Phase 2 | Recruiting | Sheng-Li Xue, MD | 42 | 2022-08-01 | 2025-11-21 |
| Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders Clofarabine, Fludarabine, Busulfan - AML, ALL | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 31 | 2020-11-20 | 2026-03-13 |
Anemia, Refractory, with Excess of Blasts (1) · Bone Marrow Failure Disorders (1) · Hemoglobinopathies (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Non-Hodgkin (1) · Myeloproliferative Disorders (1)
Anemia (1) · Anemia, Refractory (1) · Bone Marrow Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia (1) · Leukemia, Myeloid (1) · Lymphatic Diseases (1) · Lymphoma (1) · Lymphoproliferative Disorders (1) · Myelodysplastic Syndromes (1)
Busulfan (1) · Clofarabine (1) · Cyclosporins (1) · Inotuzumab Ozogamicin (1) · Mycophenolic Acid (1) · fludarabine (1) · fludarabine phosphate (1)
Memorial Sloan Kettering Cancer Center (1) · Sheng-Li Xue, MD (1) · Zhejiang University (1)
China (2) · United States (1)
Maria Cancio, MD (1)